Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 20/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.68 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.68 |
| ▸ | HTR1A | P08908 | 1/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10013425 | 0.92 | ELANE (0.68) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL2896989 | 0.91 | ELANE (0.80) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL6295870 | 0.88 | ELANE (0.81) | ELANECYP2C9CYP3A4 | |
| SCHEMBL1134170 | 0.88 | ELANE (0.81) | ELANECYP2C9CYP3A4 | |
| SCHEMBL8227499 | 0.85 | ELANE (0.64) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL8053053 | 0.85 | ELANE (0.64) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL14899948 | 0.85 | ELANE (0.77) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL9914390 | 0.84 | ELANE (0.64) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL1245778 | 0.82 | ELANE (0.74) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL7905406 | 0.82 | ELANE (0.82) | ELANECYP2C9ADRB1HTR1AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957082-B2 | Tetrahydropyrrolopyrimidinediones and their use in therapy | CHIESI FARMACEUTICI S.P.A (IT) | 2015-02-17 | — | — | US | disclosed |
| US-8957082-B2 | Tetrahydropyrrolopyrimidinediones and their use in therapy | CHIESI FARMACEUTICI S.P.A (IT) | 2015-02-17 | — | — | US | disclosed |
| US-20120202826-A1 | Tetrahydropyrrolopyrimidinediones And Their Use In Therapy | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-08-09 | — | — | US | disclosed |
| US-20120202826-A1 | Tetrahydropyrrolopyrimidinediones And Their Use In Therapy | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-08-09 | — | — | US | disclosed |
| US-8198288-B2 | Tetrahydropyrrolopyrimidinediones and their use in therapy | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2012-06-12 | — | — | US | disclosed |
| US-8198288-B2 | Tetrahydropyrrolopyrimidinediones and their use in therapy | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2012-06-12 | — | — | US | disclosed |
| US-20090093477-A1 | TETRAHYDROPYRROLOPYRIMIDINEDIONES AND THEIR USE IN THERAPY | CHIESI FARMACEUTICI S.P.A. (IT) | 2009-04-09 | — | — | US | disclosed |
| US-20090093477-A1 | TETRAHYDROPYRROLOPYRIMIDINEDIONES AND THEIR USE IN THERAPY | CHIESI FARMACEUTICI S.P.A. (IT) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202826-A1 | Tetrahydropyrrolopyrimidinediones And Their Use In Therapy | SERPINB1, ELANE, MPO | ELANE 2/4885CYP2C9 1646/4885ADRB1 2271/4885 |
| US-20090093477-A1 | TETRAHYDROPYRROLOPYRIMIDINEDIONES AND THEIR USE IN THERAPY | NOX1, NOX3, ELANE | ELANE 3/4885CYP2C9 2216/4885ADRB1 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.